ACS Nano,
Год журнала:
2025,
Номер
19(5), С. 5376 - 5391
Опубликована: Янв. 31, 2025
In
situ
vaccination
is
considered
a
promising
cancer
immunotherapy
strategy
to
elicit
tumor-specific
T
cell
response.
Live
bacteria
effectively
enhanced
the
immune
response
in
irradiated
tumors
as
it
can
activate
multiple
cells.
However,
adaptive
remains
low
since
lack
efficient
delivery
of
antigen
dendritic
cells
(DCs).
Here,
we
show
that
tumor
antigens
be
metabolically
labeled
with
azido
groups
situ,
allowing
for
their
specific
capture
by
orthogonally
engineered
Salmonella
via
bioorthogonal
chemistry.
Subsequently,
these
are
efficiently
delivered
DCs
through
active
movement
bacteria.
Intratumorally
injected
captured
and
improved
presentation
DCs.
This
increased
proportion
antigen-specific
CD8+
tumors,
further
resulting
systemic
antitumor
effects
bilateral
melanoma
mouse
model.
The
were
abrogated
Batf3-/-
mice
or
after
depletion,
indicating
dependent
on
responses.
Overall,
our
work
presents
combining
bacterial
engineering
labeling,
which
may
guide
development
vaccines
future.
Advanced Materials,
Год журнала:
2023,
Номер
unknown
Опубликована: Июль 12, 2023
Abstract
Natural
living
materials
serving
as
biotherapeutics
exhibit
great
potential
for
treating
various
diseases
owing
to
their
immunoactivity,
tissue
targeting,
and
other
biological
activities.
In
this
review,
the
recent
developments
in
engineered
materials,
including
mammalian
cells,
bacteria,
viruses,
fungi,
microalgae,
plants,
active
derivatives
that
are
used
summarized.
Further,
future
perspectives
challenges
of
such
material‐based
discussed
provide
considerations
advances
biomedical
applications.
Lactic
acid
(LA)
accumulation
in
the
tumor
microenvironment
poses
notable
challenges
to
effective
immunotherapy.
Here,
an
intelligent
treatment
microrobot
based
on
unique
physiological
structure
and
metabolic
characteristics
of
EBioMedicine,
Год журнала:
2024,
Номер
100, С. 104963 - 104963
Опубликована: Янв. 5, 2024
Glioblastoma
(GBM)
is
one
of
the
most
lethal
central
nervous
systems
(CNS)
tumours
in
adults.
As
supplements
to
standard
care
(SOC),
various
immunotherapies
improve
therapeutic
effect
other
cancers.
Among
them,
tumour
vaccines
can
serve
as
complementary
monotherapy
or
boost
clinical
efficacy
with
immunotherapies,
such
immune
checkpoint
blockade
(ICB)
and
chimeric
antigen
receptor
T
cells
(CAR-T)
therapy.
Previous
studies
GBM
have
suggested
that
few
neoantigens
could
be
targeted
due
low
mutation
burden,
single-peptide
vaccination
had
limited
control
monotherapy.
Combining
diverse
antigens,
including
neoantigens,
tumour-associated
antigens
(TAAs),
pathogen-derived
optimizing
vaccine
design
strategy
may
help
improvement.
In
this
review,
we
discussed
current
platforms,
evaluated
potential
antigenic
targets,
challenges,
perspective
opportunities
for
Nature,
Год журнала:
2024,
Номер
635(8038), С. 453 - 461
Опубликована: Окт. 16, 2024
Microbial
systems
have
been
synthetically
engineered
to
deploy
therapeutic
payloads
in
vivo1,2.
With
emerging
evidence
that
bacteria
naturally
home
on
tumours3,4
and
modulate
antitumour
immunity5,6,
one
promising
application
is
the
development
of
bacterial
vectors
as
precision
cancer
vaccines2,7.
Here
we
probiotic
Escherichia
coli
Nissle
1917
an
vaccination
platform
optimized
for
enhanced
production
cytosolic
delivery
neoepitope-containing
peptide
arrays,
with
increased
susceptibility
blood
clearance
phagocytosis.
These
features
enhance
both
safety
immunogenicity,
achieving
a
system
drives
potent
specific
T
cell-mediated
anticancer
immunity
effectively
controls
or
eliminates
tumour
growth
extends
survival
advanced
murine
primary
metastatic
solid
tumours.
We
demonstrate
elicited
immune
response
involves
recruitment
activation
dendritic
cells,
extensive
priming
neoantigen-specific
CD4+
CD8+
broader
natural
killer
reduction
tumour-infiltrating
immunosuppressive
myeloid
regulatory
B
cell
populations.
Taken
together,
this
work
leverages
advantages
living
medicines
deliver
arrays
tumour-specific
neoantigen-derived
epitopes
within
optimal
context
induce
specific,
effective
durable
systemic
immunity.
Probiotic
safely
Annual Review of Immunology,
Год журнала:
2024,
Номер
42(1), С. 317 - 345
Опубликована: Июнь 28, 2024
Regionalized
immune
surveillance
relies
on
the
concerted
efforts
of
diverse
memory
T
cell
populations.
Of
these,
tissue-resident
(TRM)
cells
are
strategically
positioned
in
barrier
tissues,
where
they
enable
efficient
frontline
defense
against
infections
and
cancer.
However,
long-term
persistence
these
has
been
implicated
a
variety
immune-mediated
pathologies.
Consequently,
modulating
TRM
populations
represents
an
attractive
strategy
for
novel
vaccination
therapeutic
interventions
tissue-based
diseases.
Here,
we
provide
updated
overview
heterogeneity
function
across
tissues
disease
states.
We
discuss
mechanisms
cell–mediated
protection
their
potential
contributions
to
autoimmune
disorders.
Finally,
examine
how
responses
might
be
durably
boosted
or
dampened
gain.
Microbial Biotechnology,
Год журнала:
2025,
Номер
18(1)
Опубликована: Янв. 1, 2025
Using
synthetic
biology
techniques,
bacteria
have
been
engineered
to
serve
as
microrobots
for
diagnosing
diseases
and
delivering
treatments.
These
can
be
used
individually
or
in
combination
microbial
consortia.
The
components
within
these
consortia
complement
each
other,
enhancing
diagnostic
accuracy
providing
synergistic
effects
that
improve
treatment
efficacy.
application
of
therapies
cancer,
intestinal
diseases,
metabolic
disorders
underscores
their
significant
potential.
impact
on
the
host's
native
microbiota
is
crucial,
microbes
modulate
interact
with
environment,
influencing
outcomes
overall
health.
Despite
numerous
advancements,
challenges
remain.
include
ensuring
long-term
survival
safety
bacteria,
developing
new
chassis
gene
editing
techniques
non-model
strains,
minimising
potential
toxicity,
understanding
bacterial
interactions
host
microbiota.
This
mini-review
examines
current
state
disease
diagnosis
treatment,
highlighting
challenges,
future
directions
this
promising
field.
Nature Communications,
Год журнала:
2025,
Номер
16(1)
Опубликована: Янв. 31, 2025
The
intricate
interactions
between
the
host
immune
system
and
its
microbiome
constituents
undergo
dynamic
shifts
in
response
to
perturbations
intestinal
tissue
environment.
Our
ability
study
these
events
on
systems
level
is
significantly
limited
by
situ
approaches
capable
of
generating
simultaneous
insights
from
both
microbial
communities.
Here,
we
introduce
Microbiome
Cartography
(MicroCart),
a
framework
for
probing
across
multiple
spatial
modalities.
We
demonstrate
MicroCart
investigating
gut
changes
murine
colitis
model,
using
proteomics,
transcriptomics,
glycomics.
findings
reveal
global
but
systematic
transformation
responses,
encompassing
tissue-level
remodeling
epithelial
cell
state
perturbations,
bacterial
population
shifts,
localized
inflammatory
metabolic
process
alterations
during
colitis.
enables
deep
investigation
interplay
with
multi-omics.
